[144] Mineralys Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. (MLYS) – Form 144 filing: Adam Levy has notified the SEC of an intended sale of 12,946 common shares through Merrill Lynch on or after 28 Jul 2025 on the Nasdaq. The shares have an estimated aggregate market value of $181,803.62, implying a per-share price of roughly $14.04. Mineralys has 65.18 million shares outstanding, so the proposed sale represents about 0.02 % of the float. Levy previously sold 10,758 shares on 11 Jul 2025 for $155,454.18. The securities being sold were acquired via (1) vesting of RSUs (6,620 shares), (2) open-market purchase (3,125 shares), and (3) Employee Stock Purchase Plan allocations (3,201 shares) between Feb 2023 and Jun 2025. The filer affirms no undisclosed material adverse information. No operational or earnings data are included in this notice.

Positive

• Sale equals only ~0.02 % of outstanding shares, indicating minimal dilution or market impact.
• Transparency under Rule 144 allows market participants to anticipate the trade and incorporate it into pricing.

Negative

• Second insider sale within three weeks may be interpreted as reduced insider conviction.
• No accompanying 10b5-1 plan disclosure could prompt scrutiny over discretionary timing.

Insights

Securities Analyst

TL;DR: Small insider sale (~$182k, 0.02% float) is immaterial to valuation; signals modest diversification rather than strategic shift.

The proposed disposition of 12.9k shares by Adam Levy is minor relative to Mineralys’ 65 m share base. Recent liquidity events (10.8k shares sold earlier in July) total $337k, still well under 0.1 % of market cap. Rule 144 filings are routine for insiders unlocking equity from RSUs and ESPP programs. With no accompanying operational disclosures, the filing carries limited read-through for earnings, pipeline progress, or financing needs. I view the development as neutral for the stock; trading volumes on Nasdaq should easily absorb the sale.

Corporate Governance Expert

TL;DR: Consecutive insider sales may raise mild governance optics, but size and timing suggest ordinary portfolio management.

Investors often scrutinize insider disposition for sentiment cues. Levy’s consecutive July sales slightly exceed 23k shares over three weeks, yet remain de-minimis versus float and consistent with equity-comp plan vesting. The filing reiterates the standard Rule 144 representation that no undisclosed adverse information exists. Absence of a disclosed 10b5-1 plan could invite questions on timing, but overall governance risk is low. Impact on shareholder perception: slightly negative, but not material.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	12946	181803.62	65175287	07/28/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/10/2023	Vesting of restricted stock unit award	Mineralys Therapeutics, Inc.			6620	03/10/2023	Granted as part of issuer equity compensation plan
Common Stock	02/10/2023	Open Market Purchase	Mineralys Therapeutics, Inc.			3125	02/10/2023	Cash
Common Stock	12/31/2023	Employee Stock Purchase Plan	Mineralys Therapeutics, Inc.			733	12/31/2023	Cash
Common Stock	06/30/2024	Employee Stock Purchase Plan	Mineralys Therapeutics, Inc.			1453	06/30/2024	Cash
Common Stock	06/30/2025	Employee Stock Purchase Plan	Mineralys Therapeutics, Inc.			1015	06/30/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Adam Levy 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	07/11/2025	10758	155454.18

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Mineralys (MLYS) shares are being sold under this Form 144?

Adam Levy intends to sell 12,946 common shares.

What is the estimated market value of the planned MLYS sale?

The aggregate market value is $181,803.62.

When will the MLYS shares be sold?

The approximate sale date disclosed is 07/28/2025.

How significant is the sale relative to Mineralys’ share count?

It represents roughly 0.02 % of the 65.18 million shares outstanding.

Were other insider sales disclosed in the past three months?

Yes, 10,758 shares were sold on 07/11/2025 for $155,454.18.